Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Zilka

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Acta Veterinaria Scandinavica|March 2, 2016
Risk factors for canine cognitive dysfunction syndrome in SlovakiaStanislav Katina, Jana Farbakova, Aladar Madari, et al.
Brain Research|December 16, 2006
Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic ratsMiroslava Hrnkova, Norbert Zilka, Zuzana Minichova, et al.
Acta Neuropathologica|April 10, 2010
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathyNorbert Zilka, Miroslava Korenova, Branislav Kovacech, et al.
Journal of Alzheimer'S Disease : JAD|September 15, 2009
Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrierAndrej Kovac, Monika Zilkova, Maria A Deli, et al.
Journal of Neuroinflammation|October 13, 2010
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's diseaseZuzana Stozicka, Norbert Zilka, Petr Novak, et al.
Journal of Neurochemistry|January 15, 2009
Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathiesJozef Hanes, Norbert Zilka, Miriam Bartkova, et al.
Neuroreport|January 25, 2003
DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitopeLubica Vechterova, Eva Kontsekova, Norbert Zilka, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Alzheimer'S Research & Therapy|December 6, 2014
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's diseaseEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Biochemical Society Transactions|July 24, 2012
The self-perpetuating tau truncation circleNorbert Zilka, Branislav Kovacech, Peter Barath, et al.
Alzheimer'S Research & Therapy|December 6, 2014
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease modelEva Kontsekova, Norbert Zilka, Branislav Kovacech, et al.
Acta Veterinaria Scandinavica|March 2, 2016
Risk factors for canine cognitive dysfunction syndrome in SlovakiaStanislav Katina, Jana Farbakova, Aladar Madari, et al.
Brain Research|December 16, 2006
Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic ratsMiroslava Hrnkova, Norbert Zilka, Zuzana Minichova, et al.
Acta Neuropathologica|April 10, 2010
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathyNorbert Zilka, Miroslava Korenova, Branislav Kovacech, et al.
Journal of Alzheimer'S Disease : JAD|September 15, 2009
Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrierAndrej Kovac, Monika Zilkova, Maria A Deli, et al.
Journal of Neuroinflammation|October 13, 2010
Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's diseaseZuzana Stozicka, Norbert Zilka, Petr Novak, et al.
Journal of Neurochemistry|January 15, 2009
Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathiesJozef Hanes, Norbert Zilka, Miriam Bartkova, et al.
Neuroreport|January 25, 2003
DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitopeLubica Vechterova, Eva Kontsekova, Norbert Zilka, et al.
Pageof 8